Skip to Main Content

Paper Details

PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer.
J Exp Med
7
2023
CDK4/6, PD-1, T cell, T cell effector populations, T cell receptor, breast and ovarian cancer, breast cancer, cancer, melanoma, mouse, patients, ribociclib, single
Author NameAffiliation
Ana C Garrido-CastroDana-Farber Cancer Institute
Ana C Garrido-CastroHarvard Medical School
Sara M TolaneyDana-Farber Cancer Institute
Sara M TolaneyHarvard Medical School
  • 1 - 4

Datasets

Release 1.2